Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.
Journal: The New England journal of medicine
Published: August 20, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: February 17, 2025
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Journal: Journal of neurology
Published: October 23, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: August 17, 2023
Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility.
Journal: Human molecular genetics
Published: December 03, 2022
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Journal: The British journal of dermatology
Published: November 23, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Journal: JAMA dermatology
Published: May 26, 2018
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 01, 2017
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 22, 2017
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Journal: The British journal of dermatology
Published: September 18, 2017
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Journal: Journal of clinical pharmacology
Published: August 31, 2017
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.
Journal: The Journal of dermatological treatment
Published: August 12, 2017
Last Updated: 09/26/2026